Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Protein Networks02:26

Protein Networks

3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Construction Of A Tp53 Mutation-associated Cerna Network As Prognostic Biomarkers In Hepatocellular Carcinoma

Construction of a TP53 mutation-associated ceRNA network as prognostic biomarkers in hepatocellular carcinoma

Dong Wang1, Wenxiang Shi2, Chenjie Qiu1

  • 1Department of General Surgery, Changzhou Hospital of Traditional Chinese Medicine, Changzhou 213000, China.

Heliyon
|May 13, 2024

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K

View abstract on PubMed

Summary
This summary is machine-generated.

This study reveals a core competing RNA network (ceRNA) linked to TP53 mutations in hepatocellular carcinoma (HCC). The findings highlight MEX3A as a key player, offering new therapeutic targets for HCC.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Hepatocellular carcinoma (HCC) poses a significant global health threat.
  • Regulatory networks involving competing endogenous RNAs (ceRNAs) are crucial in HCC pathogenesis.
  • TP53 alterations are common in HCC and influence miRNA and lncRNA expression.

Purpose of the Study:

  • To construct and analyze a ceRNA network associated with TP53 mutations in HCC.
  • To identify key regulatory RNAs and potential therapeutic targets within this network.
  • To investigate the role of MEX3A in HCC progression and its relationship with the tumor microenvironment.

Main Methods:

  • Collected TP53 mutation data from the cBioPortal database.
  • Performed differential expression analysis to identify RNAs linked to TP53 mutations.
Keywords:
Competing endogenous RNAHepatocellular carcinomaLINC00491MEX3A

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
  • Predicted lncRNA-miRNA-mRNA interactions using miRcode, miRDB, and TargetScan.
  • Constructed and visualized ceRNA networks using Cytoscape.
  • Analyzed MEX3A for methylation, mutation, protein-protein interactions, gene set enrichment, immunity, and drug sensitivity.

    • Main Results:

    • Identified a ceRNA network comprising 28 lncRNAs, 4 miRNAs, and 31 mRNAs.
    • Screened a core ceRNA network (LINC00491/TCL6-hsa-miR-139-5p-MEX3A) involving TP53-altered genes.
    • Observed decreased MEX3A methylation and increased mutation frequency in HCC.
    • Found elevated MEX3A expression correlated with changes in the HCC immune microenvironment.

    Conclusions:

    • Successfully constructed a TP53-mutation-related ceRNA network in HCC.
    • The identified core ceRNA network, particularly MEX3A, offers novel insights into HCC mechanisms.
    • This network provides potential avenues for developing new therapeutic strategies for HCC.
    TCL6
    TP53
    miR-139-5p